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1. Introduction  
In spite of the considerable progress in their diagnosis, prevention and treatment, 
cardiovascular diseases remain the number one cause of death worldwide. This is partially 
due to the rapidly growing incidence of obesity, which is a well-known independent risk 
factor for insulin resistance, diabetes, dyslipidaemia, high blood pressure and thrombosis 
(Lopaschuck et al., 2007).  
The metabolic complications of obesity, often referred to as the metabolic syndrome, 
characterized by a heterogenic complex of symptoms and consist of glucose intolerance, 
central obesity, dyslipidemia (hypertriglyceridemia, elevated nonesterified fatty acids 
(NEFAs), and decreased high-density lipoprotein (HDL) cholesterol), and hypertension. 
These, often culminating in -cell failure, impaired glucose tolerance and type 2 diabetes 
(T2D). In addition, dyslipidaemia, coronary heart disease (CHD), systemic hypertension and 
premature heart failure are pathologies related (Hubert et al., 1983). Abdominal obesity, 
ectopic lipid accumulation, hepatic steatosis, and sleep apnea can also be included in the 
metabolic complications of obesity (Parati et al., 2007).  
On the other hand, obesity leads to an alteration in the profile of hormones secreted by 
adipose tissue (adipokines). Secretion of adipocytokines has been shown particularly for 
visceral fat (Dusserre et al., 2000; Fontana et al., 2007; Yang & Smith, 2007). It is evident that 
many of these adipokines have the ability to influence other tissues such as the liver, muscle 
and brain, e.g. the adipokine leptin affects appetite regulation, others have an important 
impact on the consequences of adipose tissue inflammation (e.g. interleukin 6 (IL), PAI-1, 
monocyte chemoattractant protein 1 [MCP-1]) and vascular biology (e.g. serum amyloid A 
[SAA]) (Bastard et al., 2002; Mutch et al., 2001; Sartipy et al., 2003; Stofkova, 2009; Yang et 
al., 2006). In addition, increased tumor necrosis factor (TNF) and IL-6 expression and 
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secretion from adipose tissue are involved in both whole-body and local insulin resistance at 
different tissue sites. 
The principal purpose of this chapter is to describe how the adipocytokines and oxidative 
stress interact with insulin signaling in the context of low-grade inflammation related to 
obesity in order to promote cardiovascular complications.   
2. Pathophysiology of cardiovascular morbidity 
2.1 Introduction 
The pathophysiology of cardiovascular morbidity is complex and multifactorial. Oxidative 
stress is an important contributory factor to the etiology of many cardiovascular diseases, 
including atherosclerosis, coronary heart disease (heart attack), cerebrovascular disease 
(stroke), cardiomyopathies, peripheral vascular disease, diabetes, heart failure, and 
hypertension (Dusting & Triggle, 2005). Ischemic heart disease and hypertension are the two 
most important causes of heart failure in the Western world. Other common causes include 
valvular heart disease (especially aortic stenosis and mitral regurgitation).  
Arterial hypertension is the most prevalent cardiovascular risk factor and the leading cause 
of morbidity and mortality from cardiovascular disease (CVD) worldwide (Gómez-Marcos 
et al., 2009). Heart failure (HF) is a complex clinical syndrome caused by impaired 
ventricular performance. It is the final common pathway for a variety of cardiovascular 
disease processes, leading to potentially disabling symptoms and shortened life expectancy. 
Currently, 1% of the population aged 50–59 yr, and 10% of those over 80 yr, have HF; is the 
only major cardiovascular condition that is increasing in prevalence, because of an ageing 
population and improved survival from other CVD (Kotzé & Howell, 2008). Understanding 
these profound mechanisms of disease can help clinicians identify and treat CVD, as well as 
help patients prevent these potentially devastating complications.  
2.2 Epidemiology 
Cardiovascular diseases are the world’s largest killers, claiming 17.1 million lives a year, 
CVD contributed to a third of global deaths. An estimated 79 400 000 American adults (1 in 
3) have 1 or more types of CVD. Of these, 37 500 000 are estimated to be age 65 or older 
(Rosamond et al., 2007). 
Extensive epidemiological research has established diabetes, hyperlipidemia, hypertension, 
and cigarette smoking, as independent risk factors for CHD. The risk increases 2–3 folds 
with tobacco smoking, with age and is greater for women than for men. In contrast, cardiac 
events fall 50% in people who stop smoking and the risk of CVDs, also decreases 
significantly over the first two years after stopping smoking (Khot, et al., 2003). 
The health interview part of the National Health and Nutrition Examination Survey 
(NHANES) III was used to categorize adults over 50 years of age by presence of metabolic 
syndrome (National Cholesterol Education Program [NCEP] definition) with or without 
diabetes. The prevalence of CHD for each group was then determined. Metabolic syndrome 
(MetS) is very common, with ∼44% of the U.S. population over 50 years of age meeting the 
NCEP criteria. In contrast, diabetes without MetS is uncommon (13% of those with 
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diabetes). Older Americans over 50 years of age without MetS regardless of diabetes status 
had the lowest CHD prevalence (8.7% without diabetes, 7.5% with diabetes). Those with 
MetS without diabetes had higher CHD prevalence (13.9%) and, those with both MetS and 
diabetes had the highest prevalence of CHD (19.2%) compared with those with neither 
(Alexander et al., 2003). 
The Systematic Coronary Risk Evaluation (SCORE) data set comprises data from 12 
European cohort studies. The SCORE population was also divided into gender and age 
strata: under 40, 40–49, 50–59, and over 60. The rate of CVD mortality in each body mass 
index (BMI) category was calculated, each 5-unit increase in BMI was associated with an 
increase in CVD mortality of 34% in men and 29% in women. This increases the public 
health importance of BMI as both a simple indicator and mediator of CVD risk (Dudina et 
al., 2011). 
2.3 Pathologies associated to cardiovascular morbidity  
Impaired myocardial diastolic relaxation (e.g., diastolic dysfunction) is the earliest 
myocardial contractility observed in metabolic conditions such as obesity, insulin resistance, 
and hypertension. Diastolic dysfunction manifests as a reduction in velocity of myocardial 
relaxation, as well as decreasing myocardial compliance. Mechanisms that contribute to this 
selective cardiac dysfunction include decreases in energy production due to reductions in 
mitochondrial respiration, increased oxidative stress, and defective contractile and 
intracellular “Ca2+” regulatory proteins. Abnormalities in “Ca2+” signaling/flux and 
myofilament function contribute to the cardiomyopathic alterations observed in the 
metabolic syndrome (Ren et al., 2010). Reductions in the oxidative capacity of the 
mitochondrial electron transport chain are manifested in obese, insulin-resistant persons as 
well as diabetic patients. Mitochondria in endothelial cells are thought to play an important 
role in cellular signaling as sensors for local oxygen concentration and regulations of nitric 
oxide (NO) production. Renin-angiotensin-aldosterone system (RAAS)-mediated increases 
in nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity and generation 
of reactive oxygen species (ROS) may result in mitochondrial damage and associated 
decreases in oxidative phosphorylation, Adenosine triphosphate (ATP) production and 
bioavailable NO (Ren et al., 2010). 
The mechanisms underlying ventricular dysfunction are dysfunction of cardiac myocytes 
and longstanding pressure or volume overload. As myocardial contractility decreases, the 
stroke volume drops and the end-diastolic volume and pressure increase. If sustained in the 
long-term, this volume increase leads to what is termed cardiac remodelling. This involves 
myocardial hypertrophy, chamber enlargement and an increase in ventricular wall stress, 
and increases oxygen demand. An increase in ventricular stiffness also occurs due to 
increased collagen deposition in the heart, which impairs filling and exacerbates the 
situation (Kotzé & Howell, 2008). 
The new paradigm of atherosclerosis links oxidative stress, inflammation, thrombosis, and 
endothelial dysfunction. Growing evidence indicates that chronic and acute overproduction 
of ROS under pathophysiologic conditions is integral in the development of CVD 
(Madamanchi et al., 2005). Coronary artery disease (CAD) is one of the most frequent causes 
of death and disabling symptoms worldwide. Epidemiological studies have indicated the 
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rising prevalence of atherosclerosis globally (Tedgui & Mallat, 2006). Formation of 
atheromatous plaques in the arteries obstructs the supply of oxygen and nutrients to the 
myocardium, resulting in CHD (Woods et al., 2000).  
2.3.1 Diabetes 
Diabetes is a prime risk factor for CVD, the link between diabetes and CVD is complex and 
multifactorial. The presence of insulin resistance, impaired glucose tolerance, and overt 
diabetes, are associated with an increased risk of CVD, these conditions are also 
accompanied by the presence of oxidative stress (Woods et al., 2000). Vascular disorders 
include retinopathy and nephropathy, peripheral vascular disease (PVD), stroke, and CAD. 
Diabetes also affects the heart muscle, causing both systolic and diastolic heart failure.  
The etiology of this excess cardiovascular morbidity and mortality is not completely clear 
(Dokken, 2008). Evidence suggests that although hyperglycemia, the hallmark of diabetes, 
contributes to myocardial damage after ischemic events, it is clearly not the only factor, 
because both pre-diabetes and the presence of the MetS, even in normoglycemic patients, 
increase the risk of most types of CVD (Alexander, 2003; Dokken, 2008). In diabetes, where 
CVD is of particular concern, there are multiple sources of ROS including the auto-oxidation 
of glucose, increased substrate flux, and decreased levels of NADPH through the polyol 
pathway. Formation of advanced glycation end products (AGEs) and their interaction with 
cellular targets, such as endothelial cells, may lead to oxidative stress and promote 
formation of oxidized LDL (ox-LDL) (Ceriello & Motz, 2004). 
The recent explosion of the worldwide epidemic of MetS combining disturbances in glucose 
and insulin metabolism, excess predominantly abdominally distributed weight, mild 
dyslipidemia, and hypertension, with the subsequent development of obesity, T2D and 
CVD, compromises progress made in reducing the morbidity and mortality of CVD in 
recent years. Cardiovascular risk increases in parallel to insulin resistance (as estimated by 
the homeostasis model assessment index (HOMA) both patients with diabetes and 
nondiabetic (Saely et al., 2005). 
2.3.2 Metabolic syndrome  
The incidence of CVD, coronary heart disease, and T2D has not been well defined in persons 
with the MetS. Conclusions were that MetS is common and is associated with an increased 
risk for CVD and T2D in both sexes, according to metabolic syndrome traits. MetS accounts 
for up to one third of CVD in men and approximately half of new T2D over 8 years of 
follow-up (Wilson et al., 2005). 
A large family study of T2D in Finland and Sweden (the Botnia study) were included in the 
analysis of cardiovascular risk associated with the MetS. The aim of the study was to assess 
the prevalence of cardiovascular morbidity and mortality associated with the MetS by 
applying the WHO definition. In women and men, respectively, the MetS was seen in 10 
and 15% of subjects with normal glucose tolerance, 42 and 64% of those with impaired 
fasting glucose (IFG)/impaired glucose tolerance (IGT), and 78 and 84% of those with T2D. 
Cardiovascular mortality was markedly increased in subjects with the MetS (12.0 vs. 2.2%, 
p< 0.001). Of the individual components of the MetS, microalbuminuria conferred the 
strongest risk of cardiovascular death (RR 2.80; p< 0.002) (Isomaa et al., 2001). 
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2.3.3 Obesity 
Obesity has been increasing in epidemic proportions in both adults and children. In adults, 
overweight is defined as a BMI 25 to 29.9 Kg/m2 and obesity as BMI ≥30 Kg/m2. Other 
indexes that have been used less commonly but possibly with more predictive power 
include body fatness, waist circumference (WC), waist-to-hip ratio (WHR), and weight-to-
height ratio. A recent study of nearly 360,000 participants from 9 European countries 
showed that both general obesity and abdominal adiposity are associated with risk of death 
and support the importance of WC or WHR in addition to BMI for assessing mortality risk. 
Obesity has many adverse effects on hemodynamics and CV structure and function (Lavie 
et al., 2009).  
Elevated BMI predisposes to congestive heart failure (CHF) by promoting increased blood 
pressure, diabetes, and CHD. Factors related to obesity and hypertension, include: 
endothelial dysfunction, insulin resistance, sympathetic nervous system, substances released 
from adipocytes (IL-6, TNF-, etc.), and sleep apnea (Poirier et al., 2006).  
The role of obesity in the initiation and acceleration of tissue inflammation has been well 
studied. Excess adipose tissue can contribute to inflammation in two ways: (a) ectopic fat 
storage induces lipotoxicity, promoting an intracellular inflammatory response and (b) 
altered adipokine production in obesity contributes to the inflammatory response. It is now 
recognized that adiponectin has a role in both of these processes. Related to demonstrated 
association between hypo-adiponectinaemia and metabolic dysfunction (Cnop et al., 2003) 
the proposal provides that a replacement of adiponectin may function as pharmacological 
therapy (Chandran et al., 2003).  
2.3.4 Endothelial dysfunction 
Healthy endothelium regulates blood vessel tone, platelet activation, leukocyte adhesion, 
thrombogenesis, and inflammation. The net effect of healthy endothelium is vasodilatory, 
anti-atherogenic, and anti-inflammatory (Dokken, 2008). Endothelial dysfunction has been 
observed in patients with established coronary artery disease or coronary risk factors, both 
in the coronary and peripheral vasculature (Heitzer et al., 2001).  
As shown in figure 1, endothelial dysfunction a key factor in atherogenesis, is associated 
with an increased risk of cardiovascular events and highest risk for vascular morbidity and 
mortality. A major risk for atherosclerotic plaque rupture is aging. One possible mechanism 
is that aging is associated with endothelial cell senescence, which is a risk factor for 
endothelial apoptosis and endothelial denudation, rendering the atherosclerotic plaque 
prone to rupture (Hulsmans et al., 2011). 
A primary event in atherogenesis is the infiltration of activated inflammatory cells into the 
arterial wall. ROS can be produced from both endogenous and exogenous substances. 
Potential endogenous sources include mitochondria, cytochrome P450 metabolism, 
peroxisomes, and inflammatory cell activation. In the vascular wall, ROS are generated by 
several mechanisms, including NADPH oxidases, xanthine oxidase, the mitochondrial 
respiratory chain, lipoxygenases, and nitric oxide synthases. ROS formation can be 
stimulated by mechanical forces (e.g., stretch, pressure, shear stress), environmental factors 
(such as hypoxia), secreted factors coupled to tyrosine kinase receptors (e.g., platelet derived 
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growth factor, PDGF), and secreted factors coupled to G protein-coupled receptors such as 
angiotensin II (Lehoux et al., 2006; Dokken, 2008; Hulsmans et al., 2011). 
The general process of lipid peroxidation consists of three stages: initiation, propagation, and 
termination (Catalá, 2006). The initiation phase of lipid peroxidation includes hydrogen atom 
abstraction. Several species can abstract the first hydrogen atom and include the radicals: 
hydroxyl (−OH), alkoxyl (RO−), peroxyl (ROO−), and possibly HO2− but not H2O2 or O2−. The 
membrane lipids, mainly phospholipids, containing polyunsaturated fatty acids are 
predominantly susceptible to peroxidation because abstraction from a methylene (CH2-) 
group of a hydrogen atom, which contains only one electron, leaves at the back an unpaired 
electron on the carbon, CH-. The presence of a double bond in the fatty acid weakens the C–H 
bonds on the carbon atom nearby to the double bond and thus facilitates H- subtraction. The 
initial reaction of -OH with polyunsaturated fatty acids produces a lipid radical (L-), which in 
turn reacts with molecular oxygen to form a lipid peroxyl radical (LOO−).There they secrete 
ROS and oxidize lipoproteins, inducing foam cell formation and endothelial cell apoptosis, 
which in turn lead to plaque growth, erosion, and rupture (Hulsmans et al., 2011). 
It is now widely recognized that chronic low-grade inflammation and oxidative stress play a 
key role in the initiation, propagation, and development of metabolic disorders. The aim of 
Hulsmans et al., (2011), was to review the functional roles of various microRNAs (miRs) in 
regulating oxidative stress and inflammation in adipose and vascular tissues leading to obesity 
and atherosclerosis, in order to analyze how these processes can be linked through 
communication between cells even at a remarkable distance, thus highlighting the 
communication between inflammatory and endothelial cells. The work of Targonski et al., was 
performed to evaluate the magnitude of the association between coronary endothelial 
dysfunction (CED) and cerebrovascular events. Kaplan-Meier analysis indicated that patients 
with CED had a significantly higher cumulative cerebrovascular event rate than those without 
CED (P=0.04). Presence of CED in patients without obstructive CAD is independently 
associated with an increased risk of cerebrovascular events (Targonski et al., 2003). 
2.3.5 Dyslipidemia 
The major threat to the macrovasculature for patients with and without diabetes is 
atherosclerosis, and dyslipidemia is highly correlated with atherosclerosis, up to 97% of 
patients with diabetes are dyslipidemic (Dokken, 2008). Insulin deficiency and insulin 
resistance promote dyslipidemia accompanied by increased oxidation, glycosylation, and 
triglyceride enrichment of lipoproteins.  
Nonenzymatic glycosylation of HDL shortens its half-life and renders it less protective 
against atherosclerosis (Duell, 1991). The study of Marsuki et al., was undertaken to evaluate 
the effect, on macrophage cholesterol efflux, of functional modification of HDL by its 
glycation. They also investigated the effects of the glycation-inhibitors, metformin (MF) and 
aminoguanidine (AG), on glycated HDL-mediated cholesterol efflux. The conclusion was 
that glycated HDL particles are ineffective as acceptors of ATP-binding cassette transporter 
(ABCG1) mediated cholesterol efflux; and this may explain, at least in part, accelerated 
atherosclerosis in diabetic patients. Metformin serves as a possible candidate to restore 
impaired cholesterol efflux and reverse cholesterol transport (Matsuki et al., 2009). 
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Hypertriglyceridemia can lead to increased production of the small, dense form of LDL and 
to decrease HDL transport of cholesterol back to the liver (Poirier et al., 2006). In addition to 
the characteristic pattern of increased triglycerides and decreased HDL cholesterol found in 
the plasma of patients with diabetes, abnormalities are seen in the structure of the 
lipoprotein particles, where the predominant form of LDL cholesterol is the small, dense 
form. Small LDL particles are more atherogenic than large LDL particles because they can 
more easily penetrate and form stronger attachments to the arterial wall, and they are more 
susceptible to oxidation (Stocker & Keaney, 2004). In diabetic patients, LDL particles can 
also become glycated, in a process similar to the glycation of hemoglobin. Glycation of LDL 
lengthens its half-life and therefore increases the ability of the LDL to promote atherogenesis 
(Dokken, 2008). 
2.3.6 Atherosclerosis 
Atherosclerosis is no longer considered a pure lipid disorder. It has become increasingly 
clear that inflammation is at the root of atherosclerosis and its complications. In addition to 
playing a causal role in lesion formation, inflammation can yield predictive and prognostic 
information of considerable clinical utility. In addition to serving as biomarkers of 
atherosclerotic events, inflammatory mediators directly participate in lesion formation, 
propagation, and eventual rupture and in this fashion may represent a powerful tool to 
assess endothelial cell activation. Clearly, understanding the mechanisms and mediators of 
endothelial dysregulation and inflammation may yield new targets to predict, prevent, and 
treat cardiovascular disease (Szmitko, 2003). 
Many common conditions predisposing to atherosclerosis, such as hypercholesterolemia, 
hypertension, diabetes, and smoking, are associated with a reduced vascular availability of 
NO, a free radical that not only produces vasodilation but also has potent antiatherogenic 
properties, such as inhibition of platelet aggregation, prevention of smooth muscle cell 
proliferation, reduction of lipid peroxidation, and inhibition of adhesion molecule 
expression (Landmesser & Harrison, 2001). Impaired endothelium-dependent vasodilation, 
a surrogate for NO bioavailability, may predict cardiovascular events. Thus, the loss of NO 
not only alters vascular tone but also may explaining in part why these conditions are risk 
factors for atherosclerosis.  
3. Reactive oxygen species and oxidative stress in cardiovascular diseases 
Oxidative stress (OS) is an imbalance between production and degradation of ROS in cells, 
leading eventually to enhanced oxidative modification of biomolecules. Therefore, is a 
phenomenon associated with pathogenetic mechanisms of several diseases including 
atherosclerosis, cancer, diabetes mellitus, heart failure, hypertension, inflammatory diseases, 
as well as psychological diseases or aging processes (Naito et al., 2010). An increase in ROS 
and/or a weakening in the antioxidant defense mechanisms can cause OS. Accumulating 
evidence suggests that OS increases with age, and that therapeutic and life style approaches 
that reduce oxidative stress likely slow the development of atherosclerotic cardiovascular 
disease. Increased cellular ROS is an important contributor to the pathophysiology of 
vascular diseases, including atherosclerosis, restenosis, myocardial infarction and stroke. 
Additionally, some ROS act as intracellular messengers, and ROS accumulation activates 
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proinflammatory signaling pathways with an increased propensity for the formation of 
atherosclerotic lesions within the vessel wall (Runge et al., 2010).  
The antioxidant enzymes superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GPx) serve as primary line of defense in destroying free radicals. However, 
there are several human antioxidant genes, classified according to genes whose products are 
defined as “antioxidant enzymes” the first two groups, and genes whose products are not 
enzymes, but also deal directly with reactive species. Also, are subclassified into 3 functional 
groups: peroxidases: catalase, ceruloplasmin (ferroxidase), glutathione peroxidase 1-7, 
lactoperoxidase, myeloperoxidase, peroxiredoxin 1-6; superoxide dismutases: copper 
chaperone for superoxide dismutase, superoxide dismutase 1, soluble (amyotrophic lateral 
sclerosis 1 (adult), superoxide dismutase 2, mitochondrial, superoxide dismutase 3, 
extracellular and thiol redox proteins: glutaredoxin (thioltransferase), glutaredoxin 2,3,5, 
glutathione reductase,methionine sulfoxide reductase A, metallothionein 1A, 1B, 
1E,1F,1G,1H,1M,1X,2A, protein disulfide isomerase family A, member 6, selenoprotein P, 
plasma, 1, sulfiredoxin 1 homolog (S. cerevisiae), thioredoxin, thioredoxin 2, thioredoxin 
domain containing 1,2,3,4,5,6,8,9,10,11,12,13,14,17, thioredoxin interacting protein, 
thioredoxin-like 1, 4A, 4B, thioredoxin reductase 1,2,3 (Dusting & Triggle, 2005). 
An elevation of ROS may cause CVD due the overproduction of superoxide anion (O2-). This 
overproduction is detrimental, because of the rapid interaction of O2- with NO, which leads 
to the loss of NO bioavailability and increase in the production of peroxynitrite (ONOO−). A 
subsequent reduction in the vascular effects of NO, as well as a reduction in the 
antiatherogenic effects of NO, as a consequence will compromise cardiovascular function. An 
elevation of O2- will also lead to the oxidation of the important co-factor in the regulation of 
nitric oxide synthase, tetrahydrobiopterin (BH4), and this will lead to an “uncoupled eNOS”, 
which will then synthesize O2- rather than NO (Dusting & Triggle, 2005). 
The term ROS refers to a subset of molecules called “free radicals”, however there are some 
ROS which are not free radicals, such as hydrogen peroxide. This term refers to any 
molecule that contains an unpaired electron in the outer orbital. This unpaired electron 
makes the molecule highly reactive that leads to the formation of bonds between the ROS 
and other compounds (Dokken, 2008). Unpaired electron makes the molecule highly 
reactive, seeking to either donate an electron to another compound or take up protons from 
another compound to obtain a stable electron pair. These free radicals include superoxide 
anion (O2-), hydroxyl radical (OH), and the free radical form of nitric oxide (NO). Other 
members of the ROS family include hydrogen peroxide (H2O2) and peroxynitrite (ONOO−) 
(Dusting & Triggle, 2005). On the other hand, several enzyme systems are known to be 
sources of ROS including the mitochondrial respiratory chain, xanthine oxidase, NADPH 
oxidase, cyclooxygenase, cytochrome P450, and uncoupled eNOS. Mitochondria are the 
source of ROS. There is also growing evidence that NADPH-oxidase is a major source of 
vascular superoxide production. 
The high reactivity of free radicals leads to the formation of bonds between the ROS and 
other compounds, altering the structure and function of the tissue. Because of the reactive 
propensity of these molecules, ROS can directly damage a number of cell components, such 
as plasma membranes and organelles (Dokken, 2008). In diabetes, where cardiovascular 
disease is of particular concern, there are multiple sources of ROS including the auto-
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oxidation of glucose, increased substrate flux, and decreased levels of NADPH through the 
polyol pathway. Formation of AGEs products and their interaction with cellular targets, 
such as endothelial cells, may lead to oxidative stress and promote formation of oxidized 
LDL (Ceriello & Motz, 2004). 
Increased production of oxygen-derived free radicals such as the superoxide anion has been 
linked to impaired endothelial vasomotor function in experimental models of 
atherosclerosis. Accordingly, treatment with antioxidants has been shown to improve 
coronary and peripheral endothelial function in patients with CAD or coronary risk factors 
(Heitzer et al., 2001). Mechanisms that contribute to this selective cardiac dysfunction 
include decreases in energy production due to reductions in mitochondrial respiration, 
increased oxidative stress, and defective contractile and intracellular “Ca2+” regulatory 
proteins. Changes in mitochondrial biogenesis and function have been documented in the 
metabolic syndrome and diabetes. Alterations in mitochondrial biogenesis as well as 
mitochondrial content and function provoke a heterogeneous group of CVD risk factors that 
constitute the metabolic syndrome. (Ren et al., 2010). It is increasingly recognized that 
important aspects of mitochondrial dysfunction that contribute to CVDs are induction of 
apoptosis and changes in mitochondrial morphology under the influence of oxidative stress. 
Finally, inefficient mitochondrial oxidative phosphorylation/biogenesis and increases in 
oxidative stress appear to be overarching abnormalities contributing to cardiac diastolic 
function, the hallmark of metabolic cardiomyopathy (Ren et al., 2010).  
4. Adipocytokines and the metabolic complications of obesity   
4.1 Fat depots, adipocitokines and their relation to the human metabolic syndrome 
Adipose tissue is composed of adipocytes embedded in a loose connective tissue meshwork 
containing adipocyte precursors, fibroblasts, immune cells, and various other cell types. 
Adipose tissue was traditionally considered an energy storage depot with few interesting 
attributes. However, adipocytes express and secrete a variety of products known as 
'adipokines', including leptin, adiponectin, resistin and visfatin, as well as cytokines and 
chemokines such as TNF-, IL-6 and monocyte chemoattractant protein (Antuna-Puente et 
al., 2008) and due to the dramatic rise in obesity and its metabolic sequelae during the past 
decades, adipose tissue gained tremendous scientific interest. It is now regarded as an active 
endocrine organ that, in addition to regulating fat mass and nutrient homeostasis, releases a 
large number of bioactive mediators (adipokines) modulating hemostasis, blood pressure, 
lipid and glucose metabolism, inflammation, and atherosclerosis (see figure 1). 
During positive caloric balance there are two factors important for the development of 
metabolic disease. First one is a type of the fat accumulation, i.e., due to increase in size 
(hypertrophy) or in number (hyperplasia) of fat cells. The next factor is a place of fat storage, 
i.e. subcutaneous (SC) or visceral (Vis) fat (Wajchenberg, 2000; Bays et al., 2008). In humans, 
white adipose tissue (WAT) produces over 50 ‘adipokines’, including TNF- which 
contributes to the low-grade inflammation found in obesity, leptin which has effects on food 
intake, and a host of other agents with a variety of effects (Lago et al., 2007). In parallel with 
these proinflammatory events, WAT also produces anti-inflammatory cytokines such as 
adiponectin (which, paradoxically, tends to be lower in obese individuals) and IL-10 and 
IL1R1 (IL-1R; production of which is proportional to body weight).  
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4.2 Leptin 
Hyperleptinaemia is common in obesity and reflects increased adiposity and leptin 
resistance. Nevertheless, leptin resistance may not be complete as several actions of leptin, 
such as cardiovascular sympatho-activation, might be preserved in obese subjects known to 
be resistant to the metabolic effects of leptin (i.e. selective leptin resistance). Notably, the 
renal and sympathetic actions of leptin may play an important role in the pathogenesis of 
hypertension related to obesity and metabolic syndrome. Furthermore, the lipotoxic effect of 
leptin resistance may cause insulin resistance and ǃ cell dysfunction, increasing the risk of 
T2D. Leptin has also been shown to possess proliferative, pro-inflammatory, pro-
thrombotic, and pro-oxidative actions (Buettner et al., 2006). 
4.3 Adiponectin 
Adiponectin, referred to as adipocyte complement-related protein of 30 kDa (ACRP30), is a 
protein secreted from adipocytes (Correia & Rahmouni, 2006), that is abundantly present in 
plasma (Scherer et al., 1995; Berg et al., 2001). It is now well established that adiponectin has 
potent salutary actions on peripheral insulin sensitivity, and circulating adiponectin levels 
are reduced in obesity, insulin resistance and T2D (Scherer et al., 1995; Kern et al., 2003). 
Mice lacking adiponectin have reduced insulin sensitivity (Weyer et al., 2001; Kubota et al., 
2002; Maeda et al., 2002); in contrast, adiponectin overexpression in ob/ob mice, confers 
dramatic metabolic improvements, e.g., in various mouse models, Holland et al. (2011) show 
that the insulin-sensitizing and antiapoptotic actions of adiponectin are partly related to its 
effects on sphingolipid metabolism, providing a new unifying mechanism for the 
pleiotropic beneficial actions of adiponectin. Adiponectin stimulates the cellular activity of 
ceramidase, which removes the fatty acyl chain from ceramides. This liberates sphingosine, 
which can subsequently be phosphorylated by sphingosine kinases to generate the 
antiapoptotic metabolite sphingosine-1-phosphate (S1P). Furthermore, liver-specific 
overexpression of the adiponectin receptors, AdipoR1 and AdipoR2, increased hepatic 
ceramidase activity and, concomitantly, reduced hepatic ceramide content. These in vivo 
models of varying adiponectin expression and AdipoR1 and R2 overexpression demonstrate 
a strong association between adiponectin levels, hepatic ceramide content and insulin 
sensitivity (Holland et al., 2011). 
In the beta cell model of apoptosis, adiponectin protected against the development of 
hyperglycemia-a key feature of pancreatic insufficiency-by partially preserving beta cell 
mass and insulin content. Using mouse primary cardiomyocytes and a pancreatic beta cell 
line, Holland et al. (2011) showed that adiponectin prevents cell death induced by the 
saturated fatty acid palmitate and a short chain ceramide analog, C2-ceramide. 
Mechanistically, the insulin-sensitizing actions of adiponectin, which include enhanced 
glucose use and fatty acid oxidation (Yamauchi et al., 2003), inhibition of serine kinases that 
antagonize insulin signaling and enhanced mitochondrial biogenesis, are believed to occur 
via receptor-dependent activation of the 5′-AMP–activated protein kinase (AMPK). 
Intriguingly, it is known that adiponectin also exerts potent antiapoptotic effects and 
prevents myocardial apoptosis in response to ischemia-reperfusion injury (Shibata et al., 
2005) and lipid-induced pancreatic beta cell apoptosis (Rakatzi et al., 2004).  
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Several studies have linked hypoadiponectinemia to diabetes (Kern et al., 2003), 
hypertension (Kim et al., 2007), atherosclerosis, and endothelial dysfunction (Chow et al., 
2007). More recent studies have shown that the high-molecular weight (HMW) oligomer is 
inversely associated with the risk for diabetes independent of total adiponectin (Kadowaki 
et al., 2007), and the HMW oligomer is responsible for the association of adiponectin with 
traits of metabolic syndrome (Heidemann et al., 2008; Lara-Castro et al., 2006). On the other 
hand, adiponectin improves insulin sensitivity by increasing energy expenditure and fatty 
acid oxidation through activation of AMPK, and by increasing the expression of PPAR 
target genes such as CD36, acyl-coenzyme oxidase, and uncoupling protein-2 (Kadowaki et 
al., 2007). Alternatively, adiponectin may lead to an improved metabolic profile by the 
expansion of SC adipose tissue with decreased levels of macrophage infiltration (Nawrocki 
et al., 2006), similar to the actions of peroxisome proliferator-activated receptor (PPAR)-Ǆ 
agonists; reduction of lipotoxicity and inflammation associated with obesity (Wang et al., 
2007), and adiponectin has also had vasculoprotective effects mediated via an increase in 
endothelial nitric oxide production, or modulation of expression of adhesion molecules and 
scavenger receptors (Chow et al., 2007; Zhu et al., 2008).  
In addition, work in experimental models has shown that adiponectin mediates beneficial 
actions in cardiovascular and metabolic-associated diseases (Sam & Walsh, 2010). For 
example, in mouse models, adiponectin modulates hypertrophic signals in the heart and 
exhibits direct anti-hypertrophic properties; in addition to improving vascular function and 
pathological remodeling (Antuna-Puente et al., 2008); the hypoadiponectinemia might be 
observed in subjects with hypertension and other cardiovascular diseases and could be a 
useful pharmacologic tool to improve membrane microviscosity in hypertension, via the NO 
dependent mechanisms (Tsuda, 2011). 
It has been demonstrated that plasma adiponectin levels increased during weight reduction or 
blockade of the rennin angiotensin system indicating that adiponectin might be beneficial for 
preventing the development of atherosclerotic changes. The results of Kurata et al. indicate 
that blockade of Angiotensin II receptor ameliorates adipocytokine dysregulation and that 
such action is mediated, at least in part, by targeting oxidative stress in obese adipose tissue.  
4.4 Resistin 
Resistin is a 12-kDa peptide that was originally discovered as a result of examining 
differential gene expression of mouse adipose tissue after thiazolidinediones (TZD) 
treatment (Steppan et al., 2001). The thiazolidinediones a class of drugs that work through 
PPARǄ agonism, are insulin sensitizers and have been shown to improve cardiac risk factors 
and decrease cardiovascular events; may potentially correct the inflammatory disarray, 
endothelial dysfunction, dyslipidemia, and plaque vulnerability associated with diabetic 
cardiovascular disease through their effects on insulin resistance and fat metabolism. 
Resistin was decreased by TZD treatment of mice and was increased in insulin-resistant 
mice. Furthermore, treatment with antiresistin antibody improved insulin sensitivity and 
glucose transport in mice and mouse adipocytes, respectively (Steppan et al., 2001). 
Additional studies in mice suggest that an important site of action of resistin is on hepatic 
glucose production (Rajala et al., 2003). Therefore, resistin is clearly an important adipokine 
that likely plays a role in the development of insulin resistance; however, it appears to be 
quantitatively less important in humans than other adipokines. 
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4.5 Visfatin 
Visfatin is expressed in many cells and tissues, and was previously identified as a protein 
involved in B-cell maturation (pre-B colony enhancing factor) (Kitani et al., 2003; Samal et al., 
1994). More recently, visfatin was described to be a highly expressed protein with insulin-like 
functions, and was predominantly found in visceral adipose tissue, from which the name 
visfatin was derived (Fukuhara et al., 2005). Injection of visfatin in mice lowered blood 
glucose, and mice with a mutation in visfatin, and nicotinamide adenine dinucleotide (NAD) 
biosynthetic activity ionotropy, which is essential for -cell function (Revollo et al., 2007). In 
human studies, a positive correlation between visceral adipose tissue visfatin gene expression 
and BMI was noted, along with a negative correlation between BMI and SC fat visfatin (Berndt 
et al., 2005; Varma et al., 2007), suggesting that visfatin regulation in these different depots is 
different, and adipose depot ratios are highly dependent on the obesity of the subjects. 
Variable results were obtained regarding the relationship between visfatin and diabetes or 
insulin resistance (Varma et al., 2007; Chen et al., 2006; Hammarstedt et al., 2005; Haider et al., 
2006). Therefore, there are a number of inconsistencies among the different studies of visfatin, 
and the role of this adipokine in obesity and insulin resistance is not clear. 
4.6 Apelin 
Apelin is another short peptide released from adipocytes upon stimulation by e.g. insulin 
and the endogenous ligand of the human orphan G-protein-coupled APJ receptor. In line 
with this, plasma apelin levels are increased in obesity associated with insulin resistance and 
hyperinsulinemia (Beltowski, 2006). In the cardiovascular system, apelin elicits 
endothelium-dependent, nitric oxide-mediated vasorelaxation and in rodents, apelin also 
increases cardiac contractility in vivo (Ashley et al., 2005; Atluri et al., 2007) and causes a 
rapid fall in both arterial blood pressure and systemic venous tone (Tatemoto et al., 2001; 
Lee, 2005) with corresponding reductions in left ventricular afterload and preload (Ashley et 
al., 2005; Tatemoto et al., 2001).  
Apelin-APJ system, expressed in the central nervous system and in a variety of peripheral 
tissues, is involved in the regulation of the immune response, brain signaling, hemodynamic 
homeostasis, vasodilatation, inotropy, angiogenesis and glucose metabolism (Sorli et al., 
2006; Zhang et al., 2009). In the cardiovascular system, high expression of APJ mRNA has 
been observed in the heart (Zhang et al., 2009). Apelin expression is restricted to endothelial 
cells and negligible in cardiomyocytes in normal myocardium, but detectable in failing 
hearts (Földes et al., 2003). Of all the active fragments identified to date, apelin-13 may 
represent the most potent biological ligand (Kawamata et al., 2001). Current studies suggest 
that apelin expression is at least maintained and possibly augmented in mild, compensated 
chronic heart failure but declines in severe disease (Japp & Newby, 2008). Exogenous apelin 
administration during myocardial injury can preserve cardiac function (Chandrasekaran, 
2008). Some researchers suggested that apelin reduces infarct size and protects myocardial 
cells against ischemia-reperfusion (I/R) injury by activating the reperfusion injury salvage 
kinase (RISK) pathway. The RISK pathway incorporates phosphatidylinositol 3-OH kinase 
(PI3K)/Akt, p44/42 mitogen-activated protein kinase (MAPK) and extracellular signal-
regulated MAPK (ERK1/2) (Simpkin, 2007). 
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5. Inflammatory pathway activation and interactions with endothelial cells 
5.1 Endothelial cells 
The vascular endothelium, located at the interface of blood and tissue, is able to sense 
changes in hemodynamic forces and blood borne signals and react by synthesizing and 
releasing vasoactive substances. Vascular homeostasis is maintained by a balance between 
endothelium-derived relaxing and contracting factors. With disruption of this balance, 
mediated by inflammatory and traditional cardiovascular risk factors, the vasculature 
becomes susceptible to atheroma formation. Inflammatory mediators appear to play a 
fundamental role in the initiation, progression, and eventual rupture of atherosclerotic 
plaques.  
5.1.1 Endothelial dysfunction 
Endothelial dysfunction implies diminished production or availability of NO and/or an 
imbalance in the relative contribution of endothelium-derived relaxing and contracting 
factors, those included endothelin-1 (ET-1), angiotensin, and several oxidants. However, 
endothelial dysfunction, as assessed in terms of vasomotor dysfunction, can occur well 
before the structural manifestation of atherosclerosis and thus can serve as an independent 
predictor of future cardiovascular events (Behrendt & Ganz, 2002). 
Hypercholesterolemia, traditional cardiovascular risk factor, promotes attachment of blood 
leukocytes to the endothelium. Oxidized low-density lipoprotein causes endothelial 
activation and changes its biological characteristics in part by reducing the intracellular 
concentration of NO (Cominacini, 2001).  
On the other hand, angiotensin II can induce the production of ROS, increase the expression 
of the proinflammatory cytokines as IL-6 and monocyte chemoattractant protein-1 (MCP-1), 
and upregulate VCAM-1 on ECs. High levels of CRP can also promote endothelial 
dysfunction by quenching the production of NO and diminishing its bioactivity (Verma, 
2002). These endothelial modifications promote inflammation within the vessel wall, setting 
the stage for the initiation and progression of an atherosclerotic lesion. 
5.2 Adiponectin and inflammatory activation 
Recent research has focused on the origin of the inflammatory markers in obesity and the 
extent to which adipose tissue has a direct effect. The production of adipokines by visceral 
adipose tissue is of particular interest since their local secretion by visceral fat depots may 
provide a novel mechanistic link between obesity and the associated vascular complications. 
Under conditions of inflammation associated with cardiovascular disease, as well as an 
increase in mobilization of fatty acids from adipose tissue, there is increased secretion of 
pro-atherogenic, pro-inflammatory adipocytokines and chemokines. 
The cardiometabolic benefits of adiponectin may be driven largely through improvements 
in vascular homeostasis, especially through improving endothelial function. Some studies 
have demonstrated impaired endothelial function in adiponectin-deficient mice (Teoh et al., 
2008) demonstrated that adiponectin plays an important role to limit endothelial activation 
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and inflammation in experimental sepsis. On the contrary, in adiponectin-deficient mice 
exhibit profound reduction in survival following cecal ligation and puncture.  
5.3 Mediators of inflammation 
The inflammatory processes are mediated by several factors secreted by adipocytes 
collectively called adipocytokines (adiponectin, leptin, ghrelin, visfatin and resistin) some of 
which seem to play an important role in obesity-associated insulin resistance and 
cardiovascular complications. Tissue levels of TNF-ǂ, IL-6, leptin and visfatin were 
significantly higher in patients with CAD relative to control subjects. Significantly higher 
tissue levels of these four cytokines from abdominal fat depots were found compared to 
those from epicardial fat in CAD patients. 
IL-6 is secreted by a wide variety of cells such as endothelial cells, adipocytes, ǃ pancreatic 
cells, monocytes, and macrophages. This cytokine is essential in reducing the inflammatory 
process by promoting the synthesis of anti-inflammatory cytokines and by negatively 
regulating inflammatory targets. In humans, higher circulating IL-6 levels have been 
associated with obesity and visceral fat deposition, increased risk of impaired glucose 
tolerance, T2D and high blood pressure. IL-6 is a central mediator of the acute-phase 
response and a primary determinant of hepatic production of CRP. Visceral adipose tissue 
secretes about two to three times more IL-6 than subcutaneous tissue, secreting also other 
molecules that stimulate further IL-6 expression (Curti, 2011). 
In obesity, the pro-inflammatory effects of cytokines through intracellular signaling 
pathways involve the NF-κB and JNK systems. Thus, it can be considered that obesity 
corresponds to a sub-clinical inflammatory condition that promotes the production of pro-
inflammatory factors involved in the pathogenesis of insulin resistance (Bastard et al., 2002). 
5.4 Vasculature as part of the immune system 
Blood vessels are integral components of the immune system; they are important part in 
lymphocyte circulation and act as portals between tissue and blood compartments. 
Endothelial cells express toll-like receptors, (Kunjathoor, 2002) whose ligation induces 
expression of leukocyte adhesion molecules, inducible NO synthase 2, endothelin, IL-1, and 
other inflammatory molecules. These cells also express the scavenger receptors CD36 and 
LOX-1, and can internalize ligands such as modified LDL particles. ECs are located at the 
interface of blood and tissues, and play a pivotal role in the inflammatory response. Their 
activation causes leukocyte recruitment, increased permeability, edema, and other 
characteristic features of inflammation. Furthermore, ECs can activate adaptive immunity 
by presenting foreign antigens to specific T cells.  
5.5 Mammalian Target Of Rapamycin (mTOR) signaling pathway 
The mammalian target of rapamycin (mTOR) signaling pathway integrates both 
intracellular and extracellular signals and serves as a central regulator of cell metabolism, 
growth, proliferation and survival. Discoveries that have been made over the last decade 
show that the mTOR pathway is activated during various cellular processes (e.g. tumor 
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formation and angiogenesis, insulin resistance, adipogenesis and T-lymphocyte activation) 
and is deregulated in human diseases such as cancer and T2D (Laplante & Sabatini, 2009). In 
vivo stimulators of adipogenesis have not been clearly identified, but may include insulin, 
IGF-1, as well as certain fatty acids and/or their metabolites. Insulin/IGF-1 acts on cell 
surface receptors, activating key intracellular signaling proteins. One of these signaling 
pathways, mTOR that is binds to, and inhibited by, rapamycin, an immunosuppressant that 
blocks T cell proliferation. The mTOR protein is a 289-kDa serine-threonine kinase that 
belongs to the phosphoinositide 3-kinase (PI3K)-related kinase family and is conserved 
throughout evolution (Laplante & Sabatini, 2009). The role of mTORC1 in regulating lipid 
synthesis, which is required for cell growth and proliferation, is beginning to be 
appreciated. It has been demonstrated that mTORC1 positively regulates the activity of 
sterol regulatory element binding protein 1 (SREBP1) (Porstmann et al., 2008) and of PPAR- 
(Kim & Chen, 2004), two transcription factors that control the expression of genes encoding 
proteins involved in lipid and cholesterol homeostasis. 
The binding of insulin to its cell-surface receptor promotes the tyrosine kinase activity of the 
insulin receptor, the recruitment of insulin receptor substrate 1 (IRS1), the production of 
phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3,4,5)P3] through the activation of PI3K, 
and the recruitment and activation of AKT at the plasma membrane. In many cell types, 
activation of mTORC1 strongly represses the PI3K-AKT axis upstream of PI3K. Activation 
of S6 kinase 1 (S6K1) by mTORC1 promotes the phosphorylation of insulin receptor 
substrate 1 (IRS-1) and reduces its stability (Harrington et al., 2005). This auto-regulatory 
pathway, characterized as the S6K1-dependent negative feedback loop, has been shown to 
have profound implications for both metabolic diseases and tumorigenesis (Manning, 2004) 
and pro-inflammatory cytokines, such as TNF, activate IkB kinase-(IKK), which 
physically interacts with and inactivates tuberous sclerosis complex 1 (TSC1), leading to 
mTORC1 activation (Lee et al., 2007). This positive relationship between inflammation and 
mTORC1 activation is thought to be important in tumor angiogenesis and in the 
development of insulin resistance.   
5.6 Adiponectin as anti-inflammatory action 
Adiponectin exerts potent anti-inflammatory effects, as documented in experimental studies 
where authors demonstrate that reduces TNF-ǂ production in response to various stresses in 
plasma, adipose tissue, vascular wall, heart, and liver (Kojima et al., 2003; Ujiie et al., 2006). In 
addition, antagonizes several of the inflammatory effects of TNF-ǂ (Ouchi et al., 2003); can 
facilitate the removal of early apoptotic cells by macrophages and modulate the processes of 
inflammation and autoimmunity. This activity was mediated by calreticulin expressed on the 
phagocytic cell surface and not by any of the previously identified adiponectin receptors. 
Because the accumulation of cell corpses can cause inflammation and immune system 
dysfunction, these authors suggest a mechanism by which hypoadiponectinemia can 
contribute to the development of diabetes, atherosclerosis, and other complex diseases in 
which chronic inflammation is a contributing factor (Takemura et al., 2007). Thus, while 
AdipoR1 and AdipoR2 may mediate the metabolic properties of adiponectin (Yamauchi et al., 
2003), calreticulin controls aspects of adiponectin’s antiinflammatory actions (Hug et al., 2004). 
In vitro studies demonstrate that adiponectin adheres to injured vascular endothelium 
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(Okamoto et al., 2000) and inhibits TNF--induced monocyte adhesion to endothelial cells. It 
also decreases the expression of endothelial cell adhesion molecules (Ouchi et al., 1999) and 
TNF--induced NFkB activation (Ouchi N et al., 2000). 
Adiponectin has been shown to have a role in hepatic inflammation and steatosis. Hypo-
adiponectinaemia is associated with nonalcoholic steatohepatitis (Targher et al., 2004) and 
adiponectin has been shown to have beneficial anti-inflammatory effects in liver, reducing 
steatosis, hepatomegaly and inflammation in mouse models of alcoholic and non-alcoholic 
fatty liver disease (Xu et al., 2003). 
5.7 New mediators of inflammation and endothelial cell activation 
5.7.1 Oxidized low-density lipoprotein receptor-1 and LOX-1 
Oxidatively modified Ox-LDL and lectin-like oxidized LDL receptor-1 (LOX-1) are 
contributing factors of endothelial dysfunction, an early cellular event during atherogenesis. 
The primary receptor for Ox-LDL in endothelial cells is LOX-1. Under physiological 
conditions, LOX-1 may play a role in host defense (is expressed at low levels), whereas 
pathological states such as atherosclerosis, diabetes, dyslipedemia, hypertension 
dramatically and disease states that promote vascular injury, LOX-1 is highly expressed in 
blood vessels increase (Mattaliano et al., 2010), and may be involved in binding pro-
atherogenic materials, such as ox-LDL, that activate the endothelium. With its ability to bind 
products that induce inflammation and endothelial activation, elevated LOX-1 expression 
was observed in both initial and advanced atherosclerotic lesions (Li et al., 2002). Induction 
of LOX-1 expression is mediated by angiotensin II and endothelin-1, both antagonists of NO 
(Chen et al., 2006). LOX-1 is a type II transmembrane glycoprotein that is known to 
recognize a wide array of structurally distinct ligands besides Ox-LDL. These include 
activated platelets, AGEs, apoptotic bodies, bacteria, and CRP. LOX-1 plays a critical role in 
the development of atherosclerosis. This may suggest that increased LOX-1 transcriptional 
promoter activity may equal increased LOX-1 gene expression and elevated risk of 
atherosclerosis. Accordingly, decreased LOX-1 promoter activation may reduce the 
incidence of atherosclerosis and related diseases (Chen et al., 2006). 
5.7.2 Protease-Activated Receptors (PARs) 
Protease-Activated Receptors (PARs) are a family of 7-transmembrane–domain, G-protein– 
coupled receptors that function to link tissue injury to appropriate cellular responses, such 
as inflammation and tissue repair, which may contribute to disease. Under the influence of 
the traditional cardiovascular risk factors, the endogenous defenses of the vascular 
endothelium begin to break down, resulting in endothelial dysfunction and injury (see 
figure 1). PAR activation is also linked to the secretion of IL–6, the cytokine that promotes 
CRP synthesis, which itself triggers many of the steps in the inflammatory process. Overall, 
PAR activation appears to promote the inflammatory response within the intimal tissue, 
enhancing the initiation and progression of atherosclerotic plaques. Rosiglitazone, a 
selective PPARǄ agonist, exerts anti-inflammatory effects in both obese and T2D individuals 
by decreasing plasma concentrations of CRP, serum amyloid-A, and matrix 
metalloproteinase (Stienstra, 2007). 
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5.7.3 Lipocalin-2 
A member of the lipocalin family, lipocalin-2, also known as neutrophil gelatinase–
associated lipocalin, modulates inflammation and is another adipokine that is elevated in 
the adipose tissue of obese mouse models and in the plasma of obese and insulin-resistant 
humans. In vitro studies suggest that lipocalin-2 induces insulin resistance in adipocytes and 
hepatocytes. The plasma level of another member of the lipocalin family, lipocalin-type 
prostaglandin D synthase, serves as a biomarker of coronary atherosclerosis (Yan, 2007). 
6. Oxidative Stress in conditions and comorbidities that aggregate with 
cardiovascular disease  
Obesity, is associated with inflammation and ROS production, while advanced glycation 
end-products (AGEs), through their receptor (AGER or RAGE), play an important role on 
these processes. This is a multiligand receptor of the immunoglobulin superfamily that 
binds advanced glycation end-products. Thus, increased epicardial, pericardial (EAT), or 
subcutaneous adipose tissue (SAT) is associated with the presence and severity of 
coronary artery calcium. The AGE–RAGE engagement is widely related with CVD and 
ROS generation, mainly mediated by NADPH-oxidase. This enzyme consists in two 
membrane-bound subunits, the gp91-PHOX protein (NOX2) or some of its homologs 
(named NOX from 1 to 5) and p22-PHOX protein. Once activated, NADPH-oxidase 
produces superoxide anions from oxygen and NADPH or NADH. Enhanced ROS 
production is an important factor associated with some CVD such as CAD. Furthermore, 
Rodino-Janeiro et al. (2010, 2011) have previously observed that EAT may undergone 
higher oxidative stress than SAT in patients with CAD because of lower expression of 
some antioxidant enzymes, like catalase, and higher expression of RAGE in EAT than in 
SAT. Oxidation of phospholipids in LDL, which infiltrates into the injured vessel wall, 
results in the formation and accumulation of ox-LDL. These, is pro-atherogenic, produces 
several abnormal biological responses, such as attracting leukocytes to the intimal of the 
vessel, improving the ability of the leukocytes to ingest lipids and differentiate into foam 
cells, and stimulating the proliferation of leukocytes, endothelial cells, and smooth muscle 
cells, all of which are steps in the formation of atherosclerotic plaque. Furthermore, 
activated macrophages express scavenger receptors that internalize ox-LDL. However, 
unregulated uptake of ox-LDL leads to production of lipid-loaded foam cells (Hulsmans 
et al., 2011). 
6.1 Oxidative stress and the beta-cell 
Glucotoxicity, lipotoxicity, and glucolipotoxicity are secondary phenomena that are 
proposed to play a role in all forms of T2D. They are implicated in the pathogenesis of cell 
dysfunction (Poitout & Robertson, 2008). Hyperglycemia and hyperlipidemia follow the 
primary pathogenesis of diabetes and exert additional toxic effects on -cells. The concept of 
toxicity derived because physiologically, it presents a continuous overstimulation of the ǃ-
cell by glucose could eventually lead to depletion of insulin stores, worsening of 
hyperglycemia, and finally deterioration of ǃ-cell function. So, a prolonged in vitro exposure 
of isolated islets or insulin-secreting cells to elevated levels of fatty acids is associated with 
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inhibited glucose-induced insulin secretion, impaired insulin gene expression, and 
induction of cell death by apoptosis.  
6.2 Oxidative stress and diabetic vascular complications 
Cardiovascular risk factors promote the production of ROS, excessive generation of ROS 
and has expression of eNOS been implicated in a variety of pathological events such as 
diabetes, hypertension, atherosclerosis, ischemia-reperfusion injury, CVD and 
neurodegenerative disease (Halliwell & Gutteridge, 2007). Results from several studies 
showed that the increase in ROS levels precedes the hyperglycemia and insulin resistance, 
suggesting a causal role of ROS in the disease process. Atherosclerosis is considered as the 
underlying pathology of cardiovascular diseases such as peripheral vascular disease, stroke, 
and coronary heart disease. The pathology of atherosclerosis is complex and involves 
structural elements of the arterial wall, platelets, leukocytes, and inflammatory cells such as 
monocytes and macrophages (Libby et al., 2002; Weber et al., 2008). The endothelium is a 
dynamic interface between the arterial wall and the circulating cells. Therefore, endothelial 
dysfunction accounts for one of the primary causes of atherosclerosis. Since the endothelium 
is the major source of NO in the vasculature, loss of normal cellular function can result in 
altered NO synthesis. The endothelium provides a constitutive supply of NO from eNOS, 
and under certain conditions (e.g. inflammation) it can produce excessive NO from the 
inducible isoform of NOS (iNOS). Therefore, regulation of NOS is central in the 
development and progression of atherosclerosis. 
In particular, increased glucose leads to increased mitochondrial formation of ROS. 
Superoxide is a ROS that produces peroxynitrite when reacting with NO. Peroxynitrite 
induces cellular damage through depletion of the co-factor of the eNOS, tetrahydrobiopterin 
(BH4). Also, it activates the denominated classic pathways of diabetic complications, 
including: a) the polyol pathway, b) the AGE pathway, c) the protein kinase C (PKC) 
pathway, and d) the hexosamine pathway. Several studies suggested that intermittent low 
and high glucose conditions are even more deleterious to endothelial cell function than a 
steady, constant increase of glucose. These conditions also induce endothelial cells to enter 
into a proinflammatory state, and this state is associated with the upregulation of various 
adhesion molecules and proinflammatory cytokines (Piconi et al., 2004). 
iNOS is very relevant to diabetic pathophysiology. Recent reports reveal that decreased 
expression of eNOS accompanies increased expression of iNOS and nitrotyrosine during the 
progression of diabetes in rats (Nagareddy et al., 2005). This finding suggests that induction 
of iNOS in cardiovascular tissues is dependent on the duration of diabetes and contributes 
significantly to depressed responses to vasoactive agents. In vivo studies revealed that 
oxidative stress due to hyperglycemia, occurring before late complications, become clinically 
evident (Pitocco et al., 2009). This finding suggests that oxidative stress plays a crucial role 
in the pathogenesis of late diabetic complications. It has also been described in human 
studies that endothelial cells in diabetes fail to produce sufficient amount of NO and fail to 
relax in response to endothelium-dependent vasorelaxants e.g. acetylcholine, bradykinin, 
shear stress, etc (Avogaro et al., 2006).  
Further clinical data have demonstrated that rapid glycemic swings are associated with an 
exacerbated degree of oxidant production in human diabetes (Monnier et al., 2006), and are 
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deleterious to the endothelial function of T2D patients (Ceriello et al., 2008). Overall, these 
data outline the importance of steady glucose control and the potential involvement of 
oxidative and nitrosative stress in the pathogenesis of complications due to poorly 
controlled diabetes. Diabetic subjects have reduced antioxidant capacity which could favor 
oxidative stress. A decline in important cellular antioxidant defense mechanisms, including 
the glutathione redox system and vitamin C-vitamin E cycle, significantly increases the 
susceptibility to oxidative stress. Thus, attempts have been made to reduce oxidative stress-
dependent cellular changes in patients with diabetes by supplementation with naturally 
occurring antioxidants, especially vitamins E and C, lipoic acid levels are reduced in diabetic 
patients.  
It has now been established that measurement of F2-isoprostanes is the most reliable 
approach to assess oxidative stress status in vivo, providing an important tool to explore the 
role of oxidative stress in the pathogenesis of human disease. In addition, products of the 
isoprostane (IsoP) pathway have been found to exert potent biological actions and therefore 
may be pathophysiologic mediators of disease. IsoPs, 8-iso-PGF2ǂ and 8-iso-PGE2 possess 
potent biological effects in various systems and they also serve as mediators of oxidant 
stress through their vasoconstrictive and inflammatory properties (Kaviarasan et al., 2009). 
There exists a significant correlation between blood glucose and urinary IsoPs levels, 
suggesting that peroxidation is related to glycemic control. In vascular smooth muscle cells, 
F2-IsoPs formation was found to be induced in vitro by high glucose concentrations. 
6.3 Cardiovascular disease 
The diverse responses of the microvasculature to CVD risk factors include oxidative stress, 
enhanced leukocyte and platelet-endothelial cell adhesion, impaired endothelial barrier 
function, altered capillary proliferation, enhanced thrombosis, and vasomotor dysfunction 
(Granger et al., 2010). 
As shown in figure 1, an imbalance between the production and detoxification of ROS in 
vascular endothelial cells can result in the oxidative modification of cell components, impair 
cell function and/or can enhance cell death via apoptosis or necrosis. The oxidative 
activation of enzymes (phospholipase A2) and transcription factors (nuclear factor kB, 
NFkB) that accompanies excess ROS production can also result in an enhanced biosynthesis 
of lipids (platelet activating factor, leukotrienes) and proteins (adhesion molecules, 
cytokines) that promote inflammation. Superoxide, by virtue of its ability to inactivate nitric 
oxide (an anti-inflammatory molecule), is another link between oxidative stress and the 
induction of a pro-inflammatory phenotype in the vasculature. This oxidative stress in the 
vessel wall is often accompanied by an increased production of superoxide anion by 
circulating immune cells, and there is evidence for a causal link between these two sources 
of ROS: circulating cells and vessel wall.  
Different enzymatic sources have been implicated in the enhanced ROS production, 
including NADPH oxidase, xanthine oxidase, mitochondrial enzymes, and uncoupled nitric 
oxide synthase. It remains to clarify whether the pro-hypertensive effects of the superoxide 
anion relate to its ability to inactivate NO or to indirectly promote the production of 
endogenous vasoconstrictors, such as endothelin. NADPH-oxidase has received the most 
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attention as a potential source of ROS in hypertension (HTN), followed by xanthine oxidase. 
Both endothelial cell- and leukocyte-associated NADPH-oxidase have been implicated in 
HTN-induced superoxide production, and there is evidence linking both cellular sources of 
the enzyme to activation of the angiotensin II type 1 receptor (AT1r) and to cytokines (TNF-
) derived from circulating immune cells (Crimi et al., 2007; Harrison & Gongora, 2009). 
While some adipokines as leptin and adiponectin have been shown to promote the 
expression of endothelial cell adhesion molecules (CAMs) and leukocyte-endothelial cell 
adhesion (LECA) are known to exert an inhibitory effect on these responses. The absence of 
LECA in the microcirculation of obese mice under basal conditions suggests either that the 
pro- and anti-adhesive adipokines are in balance or that the systemic plasma levels achieved 
by these mediators do not cause overt inflammation in tissues distant from their source 
(adipose tissue). The latter possibility is supported by evidence of an increased sensitivity 
(priming) of endothelial cells and leukocytes in obese animals to inflammatory stimuli.  
However, within the microvasculature of adipose tissue, a robust inflammatory response is 
noted under basal conditions, as reflected by an increased expression of the endothelial cell 
adhesion molecules ICAM-1 and E- and P-select in, with an accompanying recruitment of 
rolling and firmly adherent leukocytes, and the formation of platelet-leukocyte aggregates. 
The reduced LECA may be linked to adiponectin deficiency since the adipokine is a potent 
inhibitor of LECA and its production/release is diminished during adipogenesis (Singer & 
Granger, 2007). 
6.4 Oxidative stress in aortic valves 
Superoxide levels also are increased in stenotic aortic valves from humans. Heistad et al., 
(2009) found, in stenotic valves removed during surgical replacement of the aortic valve, 
that superoxide is increased greatly near calcified regions of the valve. Others authors 
(Miller et al., 2008) also found, in valves obtained at surgery or autopsy, that oxidative stress 
is increased in stenotic aortic valves. Thus, in calcified stenotic aortic valves as well as in 
atherosclerotic lesions, oxidative stress is increased. But, there are important differences in 
mechanisms that account for oxidative stress in aortic valves and in atherosclerotic arteries. 
In calcific aortic stenosis, increased production of superoxide may be mediated by 
“uncoupling” of NOS, as NOS primarily produces superoxide instead of nitric oxide 
NAD(P)H expression and activity do not appear to be increased in aortic valves (Miller et 
al., 2008). In striking contrast, increased expression and activity of NADPH-oxidase appears 
to be a major mechanism for oxidative stress in atherosclerotic lesions. Oxidative stress, in 
addition to contributing to fibrosis, may activate matrix metalloproteinases (MMPs) in the 
aortic valve and arteries. In the valve, MMPs may play a permissive role in expansion of 
calcification of the valve, and degraded fragments of collagen and elastin also may increase 
pro-calcific signaling in valvular interstitial cells. Activation of MMPs in arteries probably is 
harmful in a different way, by contributing to plaque rupture. 
6.5 Atrial fibrillation 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice 
and contributes to impaired quality of life, and increased morbidity and mortality. The 
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mechanisms underlying both the initiation and perpetuation of AF are not well established 
but are thought to involve inflammation and oxidative stress. Furthermore, a number of 
studies have shown that concentrations of inflammatory mediators or markers, such as IL-6 
and high-sensitivity CRP (hs-CRP), are increased in patients with AF. One mechanism that 
may mediate the effects of inflammation in AF is oxidative stress. Elevated inflammatory 
biomarkers are strongly associated with AF. Inflammation has important prognostic 
implications in AF; large prospective studies have shown that elevated hs-CRP levels 
correlated with risk factors for stroke and overall prognosis. The positive correlation 
between elevated levels of TNF-ǂ and N-terminal pro-brain natriuretic peptide (NTpBNP) 
and severity of AF suggests that these biomarkers could be prognostic markers for AF in 
clinical practice (Li et al., 2010).  
6.6 Insulin resistance 
A large number of studies have evidenced the pivotal role of oxidative stress in insulin 
resistance states such as metabolic syndrome, obesity, and T2D (Atabek et al., 2004; Block et 
al., 2002). Decreased antioxidant capacity, increased production of ROS with oxidation 
products of lipids, DNA, and proteins have been reported in plasma, urine, and various 
tissues, suggesting systemic and organ-specific oxidative stress. Recent evidence for 
systemic oxidative stress includes the detection of increased circulating and urinary levels of 
the lipid peroxidation product F2-isoprostane (8-epi-prostaglandin F2ǂ) in both T1D and 
T2D patients (Davi et al., 2003). As described above, ROS and reactive nitrogen species 
(RNS) are able to directly modify the expression of adiponectin. Secreted almost exclusively 
from adipocytes, it is inversely correlated with fat mass in obesity and with its associated 
cardiovascular risk. It should be considered that, plasma and urinary lipid peroxidation 
markers indicative of systemic OS correlated with lower circulating adiponectin levels. 
7. Conclusion 
Figure 1 summarizes much of the content of this chapter, because it shows most of the 
cellular elements and signaling pathways in which highlights the participation of 
adipocytokines involved in the immune response and oxidative stress on the vascular 
endothelium. These alterations lead to development of atherosclerosis. And finally this 
endothelial damage, together with the increase in free radicals can cause multiorgan 
damage. 
In conclusion, abnormal adipocytokine expression with consequent inflammation, oxidative 
stress itself may result from the inflammatory changes that occur in obesity. Therefore, a 
vicious cycle that provokes increased oxidative stress in obesity may exist. Reactive oxygen 
species that lead to increased oxidative stress can be generated in adipocytes and in other 
cell types such as leukocytes, all of which can be a source of increased oxidative stress in 
obese humans. Increased oxidative stress is independently associated with obesity measures 
including body mass index and waist-hip ratio. It is also associated with several CVD risk 
factors including smoking, blood glucose, and hyperlipidemia. Oxidative stress and 
increased adipocytokines may also promote endothelial dysfunction, atherogenesis, and 
coronary heart disease independent of traditional risk factors. 
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Fig. 1. Impaired cardiovascular functions and adipocytokines actions on oxidative stress. 
This figure shows the majority of cellular elements and signaling pathways in which 
highlights the participation of adipocytokines (framed) involved in the immune response 
and oxidative stress on the vascular endothelium. These alterations lead to development of 
atherosclerosis. And finally, this endothelial dysfunction can generate harmful free radicals 
and cause tissue and multiorgan damage. 
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